Medicines such as semaglutide and tirzepatide can change appetite, weight and the daily experience of food. Those physical changes may interact with body image, identity, relationships and emotional wellbeing—even when the medicine itself is not directly causing a psychiatric effect.
What current UK safety information says
GLP-1 receptor agonists and dual GIP/GLP-1 medicines are prescription treatments used for specific indications. They have important risks and are not suitable for everyone. Use a regulated prescriber and pharmacy; products from unregulated sellers may be counterfeit or unsafe.
Following a safety review, the MHRA concluded that available evidence did not support a causal association between GLP-1 medicines and depression, suicidal thoughts or suicide. Monitoring continues, and any new or severe mental-health symptom should still be taken seriously.
The psychological side of appetite change
Less appetite or reduced preoccupation with food may feel relieving. It can also disrupt familiar routines, social connection or coping patterns. Rapid body change may attract comments or bring old body-image concerns to the surface.
People with a history of eating disorders or distress around food should discuss this with a qualified prescriber. Weight-loss medication is not a substitute for eating-disorder care.
Use medicines with proper follow-up
This article cannot determine whether a medicine is appropriate for you. Decisions belong with an authorised healthcare professional who can assess benefits, risks and follow-up needs.
- Tell the prescriber about all medicines and relevant health conditions
- Discuss pregnancy, contraception and breastfeeding advice
- Report severe abdominal pain or suspected adverse effects promptly
- Tell surgical teams you take the medicine
- Do not change insulin or other prescribed treatment without advice